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What can be inferred from limited clinical data by using current models of hepatic elimination ? 
We examined this question by analyzing previously published data on the steady-state uptake of  
the anticancer agent 5-fluorouracil (5-FU) in seven cancer patients in terms of the venous 
equilibration model, the undistributed and distributed forms of  the sinusoidal perfusion model, 
and the convection-dispersion model. Because of appreciable extrasplanchnic removal of  5-FU, 
the value of  the steady infusion rate was not used in our analysis. When the data from all patients 
were pooled by plotting the measured hepatic venous concentration against the measured hepatic 
arterial concentration, the high concentration data fell on a limiting straight line of  slope 1, 
indicating that at high dose rates elimination of  5-FU in both the liver and gastrointestinal tract 
was close to saturation. The intercept of  this line gave a model-independent estimate of Vmax/Q = 
48.0=)= 11.6 (SD) txM for the pooled data set, where Vr~ax is the maximum splanchnic elimination 
rate of S-FU, and Q is the hepatic blood flow. The low concentration data points fell on a limiting 
straight line through the origin, from which model-dependent values of the Michaelis constant 
were determined. The venous equilibration model gave Kr~ =9.4tzM, while the undistributed 
sinusoidal perfusion model gave K~m =26.5 ~M. With these values of  Kin, both models fit the 
pooled data equally well. These methods were applied to analyses of the five individual data sets 
which contained sufficiently high concentration data points. The resulting mean values were 
Vmax/Q=41.O~:5.1 (sere) IzM, Km=8.4~  l.3 tzM and K ~  =23.2#:3.2 ~M. However, the 
splanchnic region is a highly heterogeneous organ system, for which an undistributed analysis 
provides no more than an upper bound on the Michaelis constant K + (K + -<K~m). A perfusion 
model distributed to represent total splanchnic elimination is developed in the Appendix. Using 
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previous estimates of the degree of functional heterogeneity in the liver alone, this model yields 
K +~ values for individual patients which have a mean of 20.3 • 2.8 p.ML 
KEY WORDS: Michaelis-Menten kinetics; sinusoidal perfusion model; venous equilibration 
model; distributed model; convection-dispersion model; organ heterogeneity; bioavailability; 
pooling of data; kinetic parameter estimation. 
INTRODUCTION 
When substrates of hepatocellular enzymes are eliminated rapidly 
enough to display a first-pass effect and a hepatic clearance dependent on 
hepatic blood flow, any quantitative account of elimination and bioavail- 
ability of the substrate must somehow be related to hepatic physiology. 
Several quantitative liver models have been proposed for this purpose, and 
ingenious experiments with animal livers (both isolated and in situ) have 
been performed in order to discriminate between the models by precise 
statistical analyses. Such discrimination is not intended here. The present 
authors have put aside their differing views as to the relative merits of the 
models in order to examine another question: What is the impact of the 
several models on a particular set of clinical data from human subjects, 
typically more limited and less precise than data from animal preparations? 
Whatever may be the result of future discrimination between the models, 
interpretations of such data are the ultimate object of the modeling. 
5-Fluorouracil (5-FU) has been used extensively for the treatment of 
solid tumors in man. It is eliminated by the liver, kidney, and other 
extrahepatic sites (1-3) but not by the lung (4). In particular, 5-FU is 
eliminated to a significant extent in the gastrointestinal (GI) tract (3). 
Chadwick and Rogers (2) found substantial concentrations of the metabolite 
a-fluoro-/3-ureidopropionic acid (FUPA) in the epithelium of the GI tract 
after intravenous injection of 5-FU in mice, indicating that enzymes for 
metabolic degradation of the drug are located in these epithelial cells. 
In a recent study, Wagner et al. (5) investigated the hepatic elimination 
of 5-FU in man by making a series of three to six steady-state intravenous 
infusions of 2 hr duration in seven cancer patients, while sampling the 
concentration of 5-FU in the hepatic artery (CHA) and the hepatic vein 
(CHv). (Abbreviations, symbols, and Units used are shown in Table I.) 
Figure 1 presents a schematic diagram of the circulation showing the sites 
of the infusion and sampling catheters. The principal aim of the present 
paper is to devise methods to analyze this and other similar data sets in 
order to determine, for each individual patient, the appropriate kinetic 
parameters for uptake. We develop a method that is as far at possible 
independent of the assumptions of any particular mathematical model and 
unaffected by extrasplanchnic elimination. When a specific model of uptake 
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Fig. 1. Schematic diagram of the circulation, 
showing sites of sampling catheters in the 
hepatic artery (CHA) and in the hepatic vein 
(CHv), and the site of peripheral infusion I used 
in Wagner et aL (5). The dotted line encom- 
passes the splanchnic region, consisting of the 
liver and the GI tract, connected by the portal 
vein. 
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is necessary (as in the determination of the Michaelis constant Kin) , the 
data are analyzed according to a number of models currently in use, and 
their corresponding estimates of parameters are compared. 
As elimination is steady, the concentration at entry to the GI tract is 
the same as CHA. Applying Fick's law in the steady state to the whole 
splanchnic region gives 
V = Q(CHA-- CHv) (1) 
where V is the elimination rate of 5-FU in the splanchnic region consisting 
of the liver plus the GI tract (Fig. 1), and Q is the total hepatic blood flow. 
Because no blood samples were taken from the portal vein between the GI 
tract and the liver, it is not possible to apportion the total splanchnic 
elimination rate V between the liver and the GI tract. In our analysis of 
these data we therefore consider splanchnic elimination as a whole. 
Because extrasplanchnic elimination of 5-FU in man is considerable 
(1), the splanchnic elimination rate V in Eq. (1) is less than the total 
steady-state infusion rate, I. This is supported by the result of Wagner et 
al. (5) that if V is replaced by I in Eq. (1), then each set of data I, CHA, 
Cur gives a calculated value of Q much greater than hepatic blood flow 
(as high as the cardiac output). We therefore calculate V directly from 
Eq. (1) using measured steady-state values for CHA and CHv, and either 
measured or estimated values for the hepatic blood flow Q. 
In order to estimate kinetic parameters for the splanchnic uptake of 
5-FU in man, a model for such elimination in the liver and the GI tract is 
required. A number of models currently in use describe the saturable uptake 
of substances by the intact liver. These include the undistributed sinusoidal 
perfusion model (6); the venous equilibration model (7-9); the distributed 
sinusoidal perfusion model (10), and the convection-dispersion model 
(11-13). Although all these models assume that Michaelis-Menten kinetics 
hold for the interaction of substrate and enzyme, they differ in their assump- 
tions about the manner of presentation of substrate to enzyme in the 
physiological setting. The venous equilibration model assumes that all 
hepatocytes are presented with the concentration of substrate observed in 
the emergent venous blood. This model was developed for the liver alone 
and is inappropriate for elimination by the entire splanchnic region. (Are 
the enzymes in the GI tract to operate at a substrate concentration equal 
to that in the hepatic vein?) The undistributed sinusoidal perfusion model 
(6,14) is only slightly more realistic in this case. This model assumes that 
the entire organ consists of functionally identical passageways (sinusoids), 
lined with enzymes, through which the substrate passes and is progressively 
depleted, and that all sinusoids output the same substrate concentration 
into the hepatic vein. However, considering the typical division of the 
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hepatic blood flow between the hepatic artery and the portal vein, approxi- 
mately two-thirds of the substrate passes through both the GI tract and the 
liver, while the rest passes through the liver alone (Fig. 1). Such heterogeneity 
in the handling of substrate must be taken into account. This can be 
accomplished in two related ways. First, the GI tract and the liver can be 
modeled separately and then put together into a composite model, with the 
hepatic arterial blood mixing with the portal venous blood from the GI 
tract to form the input for the liver. A model of this kind is described in 
the Appendix. More generally, the splanchnic region as a whole can be 
described in terms of a single distributed (heterogeneous) model. Two such 
models have been developed and are currently in use to describe hepatic 
elimination of substrate. 
The distributed sinusoidalperfusion model (10) allows sinusoidal blood 
flows and enzyme contents to vary among sinusoids, with substrate output 
from each sinusoid mixing in the hepatic vein to form the measured output 
concentration CHv. The output concentration from such a heterogeneous 
liver is always greater than that from an equivalent undistributed liver with 
the same input concentration, and with the same total enzyme content and 
blood flow, divided equally among all sinusoids (10). More recently, the 
concept of independent, noninteracting sinusoids has been modified to 
allow for the effects of intrahepatic mixing sites (13). The convection- 
dispersion model of Roberts and Rowlands (11,12) allows heterogeneity of 
substrate transits through the liver by a different process: it abandons entirely 
the concept of independent sinusoids in favor of combining unidirectional 
convection with a generalized term to account for dispersion of substrate 
passing through the liver. 
All four models of hepatic elimination have markedly different mathe- 
matical forms and therefore may make quite different predictions as to the 
outcome of experiments, particularly if these experiments involve changes 
in hepatic blood flow. Although both the undistributed sinusoidal perfusion 
model and the venous equilibration model have received some experimental 
support, both these models have been refuted (11-20). Despite such experi- 
mental refutations, and the fact that these two models are inappropriate to 
describe total splanchnic elimination in detail, they have the advantage of 
not requiring an additional parameter to specify the heterogeneity in flow 
and enzyme activity. It is therefore useful to analyze the data of Wagner et 
al. (5) in terms of both these models (as well as the more appropriate 
distributed models). As all models share certain limiting features, some 
kinetic parameters, but not others, depend on the choice of model. In 
particular, the maximum elimination capacity of the liver (plus GI tract) 
is model-independent, whereas the Michaelis constant K~ is highly model- 
dependent. The value of Km obtained by fitting the data to the undistributed 
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perfusion model has the additional use of providing an upper bound to 
any Km obtained by fitting the same data to the distributed perfusion model. 
MODELS OF HEPATIC ELIMINATION 
The venous equilibration model (7-9) asserts that all hepatocytes are 
exposed to substrate concentrations equal to the hepatic venous concentra- 
tion CHv. For Michaelis-Menten kinetics, the elimination capacity of the 
liver is then given by 
V. ~ CHV ] 
V = m~x L CHV.~_ Km.J (2) 
where Vmax is the maximum hepatic elimination rate, and K m is the Michaelis 
constant. 
The undistributed perfusion model (6), on the other hand, takes into 
account the depletion of substrate along the hepatic blood flow so that 
hepatocytes further downstream are exposed to progressively lower substrate 
concentrations. Those at the arterial end operate at the common input 
(arterial) substrate concentration CHA , while those atihe venous end operate 
at the concentration CHV. The total elimination rate is then given by (6) 
V ~--~ V~maxl ~ g  ~ 1 (3) 
where 
= (CHA-- Cnv)/ln (CHA/CHV) (4) 
is the logarithmic mean of CnA and Cnv: CHA > C > Cnv. When applied 
to the same data set of CHA, CHV values, these two models generally yield 
different values of the kinetic parameters Vmax and Km. We thus follow the 
convention of Wagner et aL (5) and denote values fitted by the sinusoidal 
perfusion model with asterisks [Eq. (3)] while omitting them from values 
fitted by the venous equilibration model [Eq. (2)]. The measurable quantities 
CHA , CHV , and V are common to all models. 
Limiting Straight Lines 
For high venous substrate concentrations, CHV >> Km in Eq. (2); C >> K* 
in Eq. (3), we have, using also Eq. (1) 
v = Q ( C . A -  C.v)  = Vmax = V*ax (5) 
Thus, at sufficiently high substrate concentrations, the hepatic elimination 
rate approaches a maximum value that is common to all models that assume 
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Michaelis-Menten kinetics locally: all the enzyme molecules are saturated. 
In a plot of CHV against CHA, we thus expect from Eq. (5) a limiting straight 
line at high concentrations, with a slope of 1 and an intercept with the 
abscissa at CHA = Vmax/Q = V*ax/Q. In what follows, we assume that the 
maximum elimination capacity of the liver can be determined in such a 
model-independent manner from its elimination rate measured at concentra- 
tions close to those for enzyme saturation. We therefore drop the asterisk 
on Vma• determined from the sinusoidal perfusion model. Indeed, at high 
substrate concentrations, Eq. (5) applies to all models, including the dis- 
tributed perfusion and dispersion models: If  all enzyme molecules are 
saturated and working at maximum capacity, the maximum elimination rate 
of  substrate for the organ as a whole is simply the sum total of enzymatic 
maximum elimination rates, regardless of how those enzymes are distributed 
among the sinusoids, or the manner of extent of dispersion of substrate 
within the liver. Thus Eq. (5) represents the limiting straight line for all 
models at high substrate concentration, yielding a model-independent esti- 
mate of Vmax/Q. 
At the opposite extreme of low substrate concentrations, another limit- 
ing straight line is found in a plot of Cur vs. CHA. For Cur << Km in Eq. (2) 
we have, using Eq. (1) and rearranging 
CHv 1 
CHA -- Vmax (6) 
I + - -  
QKm 
On the other hand, for C<< K*  in Eq. (3) we have, again using Eq. (1) 
V = Q(CHA-- CHV) = VmaxK$ m (7) 
Using the definition of C [Eq. (4)] and canceling (CHA-- C~v) from both 
sides, we obtain, on rearrangement 
CHV - V jQ/%* 
-= e (8) 
CHA 
Equation (8) is derived in a more general way in Bass et al. (6), where it 
is shown that Eq. (8) holds provided either that V/QK*<< 1 or that 
W Vm~x << 1. 
Both Eqs. (6) and (8) describe a direct proportionality between CHv 
and CHA at low substrate concentrations 
CHV : FiCHA (9) 
where the constant of proportionality Fi is the intrinsic bioavailability, 
defined as the low concentration (first-order) limit of (CHv/CHA). The 
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interpretation of Fi in terms of the kinetic parameters, particularly Kr,, is 
highly model dependent. For the venous equilibration model we have, from 




1 + ~ - - s  14 
where Cli = Vmax/Km is the intrinsic hepatic clearance of total drug according 
to the venous equilibration model. For the sinusoidal perfusion model, on 
the other hand, Eqs. (8) and (9) give 
F i = e - v~JOr*  = e -cl*/~ (11) 
where Cl* = Vmax/K* is the intrinsic clearance according to the undis- 
tributed perfusion model. The intrinsic bioavailability Fi is determined 
directly from the data and is model-independent. It is the interpretation of 
Fi in terms of the kinetic parameters that is highly model-dependent, with 
Eqs. (10) and (11) giving interpretations of Fi according to the venous 
equilibration and sinusoidal perfusion models respectively. We note that 
Eq. (11) can be written, on expanding the exponential, as 
1 1 
F~- e Ct, /Q- 1+ CI*/ Q+ I( cI*/  Q)2 + . . .  (12) 
It is important to notice that if the development of the denominator is 
broken off after the linear term and the resulting expression is combined 
with Fick's law [Eq. (1)], one gets the same relation between Fi and Q as 
Eq. (10) in the venous equilibration model: hence CI* ~- CIi(K* ~ Km) from 
any given data. The two models differ therefore inasmuch as the terms so 
discarded are quantitatively important. It follows that the smaller Cl*/Q, 
the less the predictions of the two models differ (11). The distributed 
sinusoidal perfusion model and the convection-dispersion model also pre- 
dict limiting straight lines in a plot of CHv against CIJA at both high and 
low substrate concentrations. 
In the first-order limit of low substrate concentrations the distributed 
sinusoidal perfusion model predicts the following relation between CHA 
and CHv (15) 
Fi= Cnv I vmax l 2r wmax']2 
CHA =exp QKm LQgrcl J - R  (13) 
where e is the coefficient of variation of the (flow-weighted) distribution 
of maximum sinusoidal arterial-venous concentration differences, and is a 
measure of the degree of functional heterogeneity of the liver. For a liver 
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made up of a number of  sinusoidal groups in parallel ("notional sub- 
organs"), each consisting of identical sinusoids and having its own V(mPa~x 
and Q(P), where Zp V(mP~x = Vma• and ZpQ(P) = Q, it has been shown that e 2 
is given by (19) 
V(m~L/ V.,ax) 2 
e2=~ Q(p)/Q 1 (14) 
P 
The superscript "p"  is chosen to denote parallel elements. R is a positive 
remainder term for which there are precise upper and lower bounds, pro- 
vided that e is small enough for the quantity Vo = 1 / e -  eV~ax/QK* to be 
positive (15): 
( e { e% t - l n  1 / . .  [-Vo, Vo 2 , < R - < - l n  1 / ['Vo v 2 2"] (15) 
~zrr  L~-• i ~/27r [ ~ - + - ~ - + ~ J  
It is apparent that as e2 decreases, R falls off much faster than e z. 
The symbol ( + )  is placed on the Km in Eq. (13) to indicate that the 
Km fitted to data according to the distributed model in general differs from 
K *  fitted by the undistributed model and Km fitted by the venous equilibra- 
tion model. For experimentally determined values of F~, Vm~x, and Q, it 
follows from a comparison of Eqs. (8) [or (11)] and (13) that K+<-K * 
<< ~e (Vmax/QKm) ]. Thus the distributed sinusoidal per- [provided that R 1 2 +,2 
fusion model fits the same low concentration-limiting straight line in a plot 
of CHv against CHA by assigning a smaller value to K + than K*.  In general, 
the larger the degree of heterogeneity (represented by the parameter e), the 
more K + falls below K*.  Thus K *  provides a useful upper bound on K + 
in cases where the magnitude of e cannot be estimated directly. 
The recently introduced convection-dispersion model of  Roberts and 
Rowland (11,12) adds a generalized dispersion term (acting in the direction 
of flow) to the convection of  substrate through the liver. In the limit of 
first-order uptake of substrate, there is a mathematical correspondence 
between the dispersion coefficient D so introduced (mathematically 
analogous to, though much greater than, the molecular diffusion coefficient 
of the substrate) and the coefficient of variation e of the distributed model 
(11,13) 
e2= 2 p---~2 A-----D (16) 
~2 QL 
where A is the total cross-sectional area for flow through the liver, and p 
is the hepatocellular enzyme density along the effective length L of the 
liver; f and p2 are the mean and mean-square values of p, and the ratio 
p2/~2> 1 expresses the effect of nonuniformity of enzyme distributions in 
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the direction of flow (13). The dimensionless quantity AD/QL,  called the 
dispersion number DN, must be <<1 for the relation (16) to hold. In the 
first-order limit, therefore, the convection-dispersion model also predicts a 
straight line through the origin in a plot of CHv against CHA, with the slope 
Fi given by Eq.(13) (with R=0) ,  and e of the distributed sinusoidal 
perfusion model identified with the corresponding quantity in the convec- 
tion-dispersion model, given by Eq. (16)o 
ANALYSIS OF DATA 
P o o l e d  D a t a  
We now turn in detail to the data of Wagner et al. (5), in which the 
steady-state hepatic arterial and hepatic venous concentrations of 5-FU 
were measured during steady infusions of 5-FU into a peripheral vein 
(Fig. 1). From three to six infusions were performed on each of seven 
patients. Figure 2 shows these data in the form of a plot of Cr~v against 
CHA. Such straightforward pooling of data of this form is successful because 
C HV ~ C HV 
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Fig. 2. Plot of steady-state hepatic venous concentration C~v vs. hepatic arterial concentra- 
tion CHA in seven cancer patients. Data are from Wagner et aL (5). The straight line is the 
linear regression through 20 data points with CHA < 20/zM, constrained to pass though 
the origin. Inset shows high concentration data points (CHA> 40/IM). The straight line 
represents the linear regression through the five highest concentration points, which inter- 
cepts the abscissa at Vmax/Q =48.0+ 11.6 (SD) /zM and has a slope of 1.09~0.14 (SD). 
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at both high and low substrate concentrations the limiting straight lines are 
determined in all models by the ratio Vma~/Q (as well as by Km) and not 
by Vmax and Q separately: see Eqs. (5), (6), (8), and (13). Thus biological 
variations in liver mass, to which both Vmax and Q would be expected to 
be roughly proportional, cancel at both these limits. Such pooling would 
not in general be as successful at intermediate substrate concentrations 
where Vm~x and Q exert their influences separately. 
The limiting straight lines described in the section "Models of Hepatic 
Elimination" are recognizable in Fig. 2. Independent estimates of Kr, for 
uptake of 5-fluorouracil by isolated rat hepatocytes (21) are between 12 
and 37/xM. Consistent with these values, examination of Fig. 2. indicates 
that data points with CHA~ > 70/xM may be considered as determining the 
high concentration-limiting straight line, Eq. (5). A linear regression through 
these five highest concentration points has a slope of 1.09 • 0.14 (SD) and 
an intercept V m a x / o  =48.0• 11.6 (SD)/xM (see Fig. 2, inset). The slope is 
not significantly different from unity, which implies that at such high 
concentrations of 5-FU, elimination by both the liver and the GI tract is 
saturated. This precludes the possibility of significant elimination of 5-FU 
in the GI tract by a nonsaturable process such as passive loss into the 
intestinal lumen. This is consistent with the results of Chadwick and Rogers 
(2), who showed that after intravenous injections of 5-FU, metabolites of 
5-FU found in the gastrointestinal endothelium and in the liver were similar. 
This indicates that similar enzymatic elimination processes are taking place 
in the GI tract as in the liver. 
The limiting straight line through the origin is apparent for data points 
with CnA ~< 20 tz M, CHv ~< 5 ~ M (C ~< 10 ~ M). This range is consistent with 
K m values measured for isolated rat hepatocytes (21). We thus use the 20 
lowest concentration data points to estimate Fi using Eq. (9) by means of 
linear regression constrained to pass through the origin (Fig. 1), giving 
Fi = 0.163. This intrinsic bioavailability, Fi, given directly by observables, 
is model-independent. However, its interpretation in terms of the kinetic 
parameters Kin, Vma• and Q is model-dependent. For the venous equilibra- 
tion model, Fi is given by Eq. (10). Using Vma• gives K m  = 
9.4/~M, while for the same value of Vm~/Q the sinusoidal perfusion model 
[Eq. (11)] gives K * =  26.5/zM. Without an estimate of the degree of func- 
tional heterogeneity of the total splanchnic region consisting of liver plus 
GI tract, characterized by the parameter e 2, w e  cannot make an outright 
estimate of K+m, the value of the Michaelis constant predicted by Eq. (13) 
of the distributed sinusoidal perfusion model. However, as noted in "Models 
of Hepatic Elimination," K + -< K*, so that K +-< 26.5/xM from the pooled 
data of Wagner et al. (5). Closer estimates of K + are given in the Appendix 
and Conclusions. 
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We note that in the context of the venous equilibration model, the 20 
data points used to determine Fi have CHv values less than about 40% of 
our estimated value of Km (9.4 tzM), thus validating their use in the determi- 
nation of Fi. The five highest concentration data points have CHv values 
more than three times the estimated value of Kin, justifying their inclusion 
in the determination of Vmax/Q. Similarly for the sinusoidal perfusion model, 
the highest value of C of the 20 data points used in the determination of 
Fi is less than one-third of K*m (26.5/xM), whereas the 5 highest concentra- 
tion data points have C values of more than 1.8 times K*. 
Analysis  of Individual Patients 
Using the information gained from our analysis of the pooled data 
from all seven cancer patients studied by Wagner et al. (5) (by their Method 
1), we devised methods for analyzing the fewer data from each individual 
patient. In particular, only four of the seven individual data sets included 
a steady-state hepatic arterial concentration CHA--> 70/~M. (This included 
Patient #4, who was studied on two separate occasions). From our study 
of the pooled data (Fig. 2), we saw that the slope of the straight line through 
the five highest concentration data points was not statistically significantly 
different from 1, indicating saturation of both the liver and the GI tract at 
these concentrations. We therefore calculated Vmax/Q for each of these 
patients from their single highest concentration data point using Eq. (5). 
(This is equivalent, in a plot of CHV against CaA, to drawing a straight line 
with slope 1 through the relevant point, with the intercept of this straight 
line with the abscissa giving Vmax/Q.) Values of Vmax/Q calculated in this 
way are given in Table II, and have a mean value of 41.0• (SEM)/zM, 
compared with 48.0 tzM for the pooled data. 
The intrinsic bioavailability Fi can be determined for each individual 
patient in the same way as for the pooled data set, by forming a linear 
regression through the lowest concentration data points CHV, CHA, con- 
strained to pass through the origin. Restricting ourselves to values of 
CHA -< 20/zM as before, we find that most patients have three or more data 
points in this range (Table II). Values of Fi calculated for individual patients 
are given in Table II. The mean of the individual Fi determinations is 
0.179• (SEM), which compares with Fi=0.163 obtained from the 
pooled data. 
As with the pooled data analysis, in order to determine K~ values from 
the individual Fi values, a particular liver model must be chosen. For the 
venous equilibration model, Eq. (10) was used with individual values of 
Vmax/Q (where available) to determine the Km values given in Table II. 
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model, we used Eq. (11), again with individual Vmax/Q values to obtain 
K* values with a mean of 23.2 + 3.2 (SEM) ~M. These compare favorably 
with values obtained from the pooled data of 9.4 tzM and 26.5/zM for the 
venous equilibration and sinusoidal perfusion models respectively. 
Values for the hepatic blood flow Q were measured directly in three 
patients (Table II), allowing values of the maximum elimination rate Vmax 
to be determined from the V~ax/Q ratios. These values ranged from 21.0 
to 27.9 ~mole min -1 (Table II). 
CONCLUSIONS 
When CHA and CHV are measured across the Michaelis-Menten range 
of concentrations (above and below Km), two model-independent quantities 
may be determined, one from the limit of high (saturating) substrate con- 
centrations, and the other from the first-order limit at low substrate con- 
centrations, at which CHV is proportional to Cng. At high concentrations, 
a plot of CHv against CHA for all seven patients studied by Method 1 of 
Wagner et al. (5) tends to a limiting straight line with a stope not significantly 
different from 1 (Fig. 2, inset), indicating that elimination in both the liver 
and GI tract is saturated. This result precludes significant first-order elimina- 
tion in the GI tract (for example, by diffusion of 5-FU into the lumen). The 
intercept of the limiting straight line with the abscissa gives an estimate of 
Vmax/Q for the pooled data, where Vmax = L G Vma x-l- Vma x is the sum of the 
maximum elimination rates of the liver and the GI tract, of 48.0 + 11.6 (SD) 
/z M (see the section "Analysis of Data" and Fig. 2, inset). The contributions 
of the liver and the GI tract to this total could not be separated because 
the 5-FU concentration in the portal vein was not sampled. Estimates Of 
Vmax/Q for individual patients are given in Table II. In those cases in which 
a value for the hepatic blood flow Q is also available, an estimate of Vmax 
is also given in Table II. Estimates of V~ax/Q (or Vmax) calculated in this 
way are common to all the models of elimination discussed in this paper, 
and are thus considered model-independent in the present context. 
At the other extreme of low substrate concentrations (Cr~A<< Kr~), all 
models predict direct proportionality between CHv and CHA: a plot of CHv 
against CHA tends towards a limiting straight line through the origin as low 
substrate concentrations are approached. Such a limiting straight line is 
clearly observed in Fig. 2 in the pooled 5-FU uptake data of Wagner et al. 
(5). However, the models differ markedly in their interpretation of the slope 
of this straight line--the intrinsic bioavailability Fi--in terms of the param- 
eters Vm~x, Q, and Km. Thus, for the pooled data, the venous equilibration 
model gives an estimate of K m of 9.4 tzM, whereas the undistributed 
sinusoidal perfusion model gives K* = 26.5 tzM. With these values of Kin, 
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both models fit the data equally well (for the totality of pooled data points, 
the sum of squares of differences between predicted and measured values 
of CHv are 1338 and 1505/zM 2 for the venous equilibration and sinusoidal 
perfusion models, respectively). It is interesting (though not essential in 
our analysis) that both these values of Km are close to or within the range 
of between 12/xM and 37/zM reported for isolated rat hepatocytes by 
Mentre et al. (21). 
As noted in the Introduction, the anatomy and the arrangement of 
blood flow through the total splanchnic region do not lend themselves to 
a direct application of either the venous equilibration or the undistributed 
sinusoidal perfusion model, even if we disregard the refutations of these 
models in isolated livers (11-13, 15-18, 20). In addition, analyses of the 
uptake of various substrates by the intact liver have shown that the liver 
alone has a significant degree of functional heterogeneity characterized by 
the parameter e 2 (see, for example, refs. 10, 15, 19, 20). In the Appendix 
we therefore outline a composite model of the splanchnic region in which 
a minimum degree of heterogeneity is taken into account. The liver and GI 
tract are modeled according to the distributed and undistributed forms of 
the sinusoidal perfusion model, respectively. A composite eliminating organ 
is then modeled by assuming that blood from the hepatic artery mixes with 
blood from the portal vein before entry into the liver. The heterogeneity of 
this model is characterized by the parameter e given by Eq. (A3). Gustavsson 
et al. (3) have estimated that in mice, some 15% of total 5-FU elimination 
occurs in the GI tract, while about 23% is eliminated in the liver (at an 
infusion rate of 5-FU of 0.625 mg kg -1 hr-1). Assuming that these ratios 
Vma x and (in humans), then roughly reflect the relative magnitudes of c L Vnlax 
Eq. (A3) becomes: 
e2 = 0 .39(1-1)+0.61e~ (17) 
where A is the fraction of the total hepatic blood flow Q that passes through 
the portal vein (see Appendix). 
Past estimates of e 2 for the liver alone include e~ = 0.12 for the uptake 
of taurocholate by isolated perfused rat livers [data of Pries et al. (22), 
analyzed in ref. 13]; e~= 0.137 for uptake of colloidal CrPO4 by rat liver 
[data of Bauer et al, (14), analyzed in ref. 15]; e ~ 0 . 1 8 2  for galactose 
uptake by rat liver [data of Keiding and Chiarantini (17), analyzed in 
ref. 23], and e~ = 0.196 for galactose elimination by isolated pig livers [data 
2 fo r  n o r m a l  of Keiding et aL (24), analyzed in ref. 20]. No estimates of eL 
human livers exist in the literature. However, it has been shown for galactose 
elimination that in one cirrhotic patient (data from K. Winkler, private 
communication), about 36% of total hepatic blood flow is shunted past the 
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functional enzymes (25). Such intrahepatic shunts are a special case of 
heterogeneity, and an equivalent value for e~ corresponding to a particular 
shunt can be calculated (19); for a 36% shunt, e:L=0.56. It is, however, 
unlikely that normal human livers would have such a high degree of 
intrahepatic shunting. 
The magnitude of K+m estimated by means of the distributed sinusoidal 
perfusion model depends on e 2 according to Eq. (13): the larger e 2, the 
smaller is the estimated value of K+m. The size of e 2 in turn depends on e 2 
according to Eq. (17). For the pooled 5-FU uptake data of Wagner et al. 
(5), /~ = 0.163 and V~ax/Q =48.0/zM; for R =0,  the calculated values of 
K+m as a function of e~ are shown in Fig. 3 for h = 0.7, 0.75 and 0.8. Also 
shown in Fig. 3 are calculated values of Km and K *  from the venous 
equilibration and undistributed sinusoidal perfusion models (horizontal 
arrows). Values of e 2 previously estimated from other data sets are shown 
as vertical arrows on the abscissa. For e2L = 0.20 and h = 0.75 we have from 
Fig. 3 that K+m=23/zM, and from Eq. (17) that e2=0.125. From Eq. (15) 
the remainder term R lies in the range 0.018 < R-< 0.019, which is less than 
10% of the previous term in the expansion (13), thus justifying its neglect 
in our calculations of K+m in this case. For larger values of e 2, R becomes 
relatively larger: for e2L = 0.56, R is more than one-third of the previous 
term in Eq. (13). At such high values of e 2, estimates of K+m given by Fig. 3 
can be used only as a rough guide. Values of  K+m calculated according to 
Eq. (13) with R = 0, e 2= 0.125 and using values of Vmax/Q for individual 
patients, are given in Table II. They have a mean value of 20.3 + 2.8 (SEM) 
/zM, which is within 13% of the upper bound to Km given by the undis- 
tributed sinusoidal perfusion model. 
The foregoing numerical estimates of kinetic parameters show that the 
several models differ substantially in their interpretations of  the data, so 
that an ultimate decision between the models is desirable. It is also apparent 
that such a decision cannot be reached on the basis of clinical data alone: 
Modeling theory is at present ahead of experiment in the sense that clinical 
data do not determine all the model parameters unambiguously. We do not 
view this as a deficiency of  the models, because one of  the roles of  theory 
is to motivate future experimental designs and methods of measurement. 
Whereas validation of models is best based on studies of groups of 
subjects, the ultimate use of  the models pertains to individual patients, as 
attempted here. Estimates of the kinetic parameters Vmax and Krn have 
evident clinical importance for individual patients, especially for the choice 
of  dosage of  toxic drugs such as 5-FU. Whereas a steady infusion rate 
I < Vmax results in a steady, controlled concentration in the body, an increase 
of ! to a value exceeding V~ax leads to concentrations tending to arbitrarily 
large values. While an estimate of Vma x is thus especially useful for choices 
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Fig. 3. Variation of K+~ with the degree of heterogeneity e~ of the 
liver, from the pooled data of Wagner et  al. (5) and based on the 
distributed sinusoidal perfusion model [Eq. (13)], with V m a x / Q  = 
48.0 tzM, F i = 0.163 and R = 0. Curves are drawn for three values 
of the fraction (h) of the total hepatic blood flow passing through 
the portal vein. Total splanchnic heterogeneity e is given by Eq. 
(17). Note that for e L = 0, K+m is still slightly less than K*~ estimated 
from the undistributed model (upper horizontal arrow) due to 
heterogeneity associated with the GI tract-hepatic artery system. 
The lower horizontal arrow shows K~ estimated by the venous 
equilibration model. Vertical arrows on the abscissa show previously 
estimated values of e2: (a) taurocholate elimination by isolated rat 
livers (13,22); (b) colloidal C r P O  4 elimination by RE system of rat 
liver (14,15); (c) and (d) galactose elimination by isolated pig livers 
(17, 20, 23, 24); (e) galactose elimination by cirrhotic human liver 
(25). 
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of steady infusions, an estimate of K~ for each individual patient is useful 
for controlling the delivery of drugs in bolus inputs. As long as the substrate 
concentration in the bolus is well below K m (first-order kinetics), the hepatic 
extraction fraction is independent of concentration and hence of dose 
delivery. When the bolus concentration approaches and exceeds g m ,  the 
extraction fraction falls as concentration is increased: in the limit V ~ Vmax, 
the hepatic extraction fraction tends to zero, and bioavailability CHv/CHA 
tends to unity. As the onset of these nonlinear phenomena is controlled by 
the value of Kin, its estimate (together with that of Vr.a• for each individual 
patient is a prerequisite of rational dosing. Furthermore, changes in the 
hepatic extraction fraction with changes in hepatic blood flow (in exercise, 
cardiac failure, after meals, etc.) and with pathological changes in liver 
heterogeneity (as in intrahepatic shunting in cirrhosis) are of clinical interest. 
These considerations illustrate the clinical importance of the choices and 
uses of the models of hepatic elimination. 
APPENDIX: ELIMINATION BY LIVER PLUS GI TRACT 
We describe a composite model for steady-state Michaelis-Menten 
elimination of a substrate by both the liver and the GI tract, as shown 
schematically in Fig. 4. Blood with substrate at a concentration CHA enters 
both the hepatic artery and the GI tract at flow rates ( 1 -A)F  and AF 
respectively, where F is the rate of total hepatic blood flow and A is the 
fraction of F that is contributed by the portal circulation (Figs. 4 and 1). 
Substrate is eliminated from the blood during passage through the GI 
tract, which outputs into the portal vein. We adopt the common assumption 
of complete prehepatic mixing of portal and hepatic arterial blood. As a 
cHV, Q < 
LIVER 
v&,, 
Km G.Ii TRACT 
V%,K 
1 < CHA,(I_A,)Q 
l 
~ c P v  ~Q 
Fig. 4. Schematic diagram of composite model of splanchnic region described in the 
Appendix, consisting of three suborgans. Arterial blood, concentration CHA , enters 
the hepatic artery and the portal circulation passing through the GI tract, with flows 
of (1-A)Q and AQ respectively, where Q is total hepatic blood flow. Substrate is 
eliminated in the GI tract but not in the hepatic artery; blood from these two parallel 
suborgans is then mixed before entering the liver, where substrate is further eliminated 
before being output into the hepatic vein at a concentration CHV. 
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result of hepatic elimination, the observed hepatic venous concentration is 
C H V  9 
Let the maximum elimination capacity of the liver be given by L V m a x ~  
and that of the GI tract by Vm~ax. Let us assume that the elimination process 
is such that the Michaelis constant Km is the same in both liver and GI 
tract. This assumption is consistent with the finding of similar metabolites 
of 5-FU in the epithelium of the GI tract as in the liver following intravenous 
injections of 5-FU in mice (2). The splanchnic region as a whole can then 
be represented schematically as in Fig. 4, consisting of three suborgans. Of 
these, the GI tract and the hepatic artery are functionally in parallel (the 
hepatic artery acts essentially as a shunt). In series with these is the liver 
itself which receives as its input the mixed output from the GI tract and 
the hepatic artery. Let us assume, for simplicity, and in the absence of any 
data concerning its functional heterogeneity, that the GI tract eliminates 
substrate according to the undistributed sinusoidal perfusion model. Then 
the composite organ, representing the GI tract and hepatic artery in parallel, 
can be characterized by the parameter eo which can be calculated from 
Eq. (14). Letting Q ( 1 )  = AQ, Vmax'(1) = VC~max for the GI tract, and Q(2)= (1 -A)Q,  
V(2) max = 0 for the hepatic artery shunt gives, from Eq. (14) 
1 
e ~ = - - 1  (A1) 
A 
Since we have neglected any contributions to heterogeneity from the GI 
tract alone, Eq. (A1) represents a lower bound to the true e~. 
The splanchnic region is now reduced to two suborgans in series: the 
GI tract/hepatic artery suborgan, with e~ given by Eq. (A1), and the liver 
itself, with heterogeneity characterized by 2 eL. These two suborgans are 
connected by an intraorgan mixing site. The method of calculation of the 
composite value for e 2 for a number of distributed suborgans in series, each 
separated by a site of mixing, has been described previously for first-order 
uptake of substrate (13), and is given by 
r V(L) I ~ 
where s denotes elements in series, and where V, nax is the total maximum 
elimination capacity. In our present example, e~l) = E 2 ,  - - m a x  v(1) = Vmax,C and 
2 W(2) __ L E~2) = E L ,  - - m a x  - -  V . . . .  SO that Eq. (A2) gives for the splanchnic region as 
a whole 
V m a x  
(A3) 
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Vmax+ V . . . .  E q u a t i o n  (17) is an  a p p l i c a t i o n  o f  this  resul t .  where Vma x ~- G L 
Thus ,  in t he  f i r s t -o rder  l imi t ,  the  c o m p o s i t e  m o d e l  o f  t he  s p l a n c h n i c  r e g i o n  
s h o w n  in Fig.  4 is d e s c r i b e d  in t e rms  o f  a s ing le  d i s t r i bu t ed  s i n u s o i d a l  
p e r f u s i o n  m o d e l  w i th  a m a x i m u m  e l i m i n a t i o n  ra te  Vmax = Vmax~ + Vmax,L a n d  
the  v a l u e  fo r  e 2 g iven  by  Eq .  (A3).  
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